Chai, an AI startup serving the pharmaceutical industry, has closed a $400M Series C funding round backed by major investors. The company already counts Eli Lilly and Pfizer among its users, indicating that AI-powered drug discovery is gaining real traction in one of the world's most capital-intensive industries.
Summaries like this, in your inbox every morning.
Sign up free →What happened
Chai, an AI company that provides drug-discovery tools to pharmaceutical firms, raised $400M in Series C funding. The company's technology is already in use by Eli Lilly and Pfizer.
Why it matters
Drug discovery is capital-intensive and time-consuming; AI tools that accelerate the process can reduce costs and speed new medicines to market. Chai's ability to attract major funding and secure blue-chip pharma clients signals that AI-driven drug discovery is moving from experimental to mainstream.
What to watch
The funding will fuel Chai's expansion in AI for pharmaceutical development. The backing from major investors underscores confidence that the company's approach addresses a real bottleneck for Lilly, Pfizer, and likely other drug makers seeking to deploy AI at scale.
Chai, a company focused on artificial intelligence for drug discovery, announced a $400M Series C funding round. The capital will fuel the company's expansion in AI-powered pharmaceutical development. Among Chai's current users are Eli Lilly and Pfizer, two of the world's largest pharmaceutical companies, indicating that the startup's technology has already gained real-world adoption in the sector. The funding underscores growing investor appetite for AI tools that can streamline drug development—a process historically marked by long timelines, high failure rates, and enormous capital expenditure. By securing both major pharmaceutical clients and substantial venture backing, Chai has demonstrated that its approach resonates with both end-users seeking to accelerate discovery and investors betting on the commercial viability of AI in healthcare.
Chai's $400M Series C reflects a broader shift in pharmaceutical development toward AI-assisted drug discovery. Historically, bringing a new drug to market has required years of research and billions in investment; any technology that shortens timelines or reduces costs addresses a genuine constraint for companies like Eli Lilly and Pfizer. The fact that these industry giants have already deployed Chai's tools—rather than building proprietary solutions—suggests the startup has solved a problem that even well-resourced R&D teams find difficult. The scale of funding backing this round points to investor confidence that AI in drug discovery is no longer speculative; it is becoming embedded in how the world's largest pharma firms operate.
No comments yet. Be the first to share your thoughts!
Log in to join the discussion
Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.
Get Started FreeFree · takes 30 seconds · unsubscribe anytime
1 minute a day. The AI essentials.
200+ sources · Email / LINE / Slack
